Medicina e società
Autismo e medicine alternative
AUTISM AND ALTERNATIVE MEDICINE
DANIELA MARIANI CERATI1, CARLO HANAU2
1Azienda Ospedaliera S. Orsola - Malpighi, Bologna;
2Docente di Programmazione e Organizzazione dei Servizi sociali e sanitari, Università di Modena e Reggio, Corso di Laurea in Scienze dell'Amministrazione dei Servizi sociali e sanitari
Settembre 2005 - pagg. 465 -468
Abstract
Autism is an oligogenic disease, the phenotipic expression of which depends on post-conceptional
factors not yet identified. To identify these factors, as well as possible palliative
treatments, is among the expectations of parents of autistic children and among the priorities
of the entire research community. However, parents’ expectations are often in conflict with those
of the research community, since, too often, they leave the door open to the so-called “hope
therapies” which are not evidence-based. Hence, there is the need of pilot studies which
can lead to long-term, randomised and well controlled studies, possibly based on a large number
of cases, in order to give satisfactory questions with regard to autism.
Parole chiave
Classificazione MeSH
Bibliografia
1. AA.VV. Emilia Romagna, La Promozione della
salute per le persone affette da autismo e disturbi
pervasivi dello sviluppo, Documento
tecnico. Il bollettino dell’ANGSA, anno 17, N.
4/5/6, 2003,130-206.
2. Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with autism. J Child Psychol Psychiatry 2004;45(2):212-29.
3. Lomascolo T, Vaccaio A, Villa S. Autismo: modelli operativi nei servizi. Vannini editrice, 2003.
4. AA.VV. (modificato da Giovanardi, et al. 2001) Allegato VI. Protocollo di valutazione di eventuali patologie associate e di ricerca eziologica nella diagnosi di autismo/DPS. Assistenza alle persone affette da disturbi dello spettro autistico. Dossier 103-2004, Regione Emilia-Romagna, Agenzia Sanitaria Regionale, Bologna, 2005,77-8.
5. Buitelaar JK. Why have drug treatments been so disappointing? Novartis-Found-Symp 2003;251:235-44; discussion 245-9, 281-97.
6. Volkmar FR, Pauls D. Autism, Lancet 2003; 362:1133-41.
7. Montinari M. Autismo: nuove terapie per migliorare e guarire. Macroedizioni, 2002.
8. Shaw W. Biological Treatments for Autism and PPD, revised 2002 edition, con il contributo di Rimland B, et al., edito a cura dell’Autore, Lenexa, USA, 2002.
9. Verzella F, DAN! Italy 2005 (dal sito www.iodellasalute. it), febbraio 2005.
10. Wakefield AJ, Anthony A, Murch SH, Linnell J, Casson DM, Malik M, et al. Ileallymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-41.
11. Hyman S, Levy S. Autistic spectrum disorders: when traditional medicine is not enough. Contemporary Pediatrics 2000;10: 101-12.
12. http://www.autismwebsite.com/ari/dan /pangborn.htm
13. Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Vaisanen ML, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000;15:429-35.
14. Reichelt KL, Knivsberg AM, Hoeien T, Noedland M. A randomised controlled study of dietary intervention in autistic syndromes. Nutritional Neuroscience 2002; 5(4):251-61.
15. Millward C, Ferriter M, Calver S, Connell- Jones G, Gluten- and casein-free diets for autistic spectrum disorder. The Cochrane Database of Systematic Reviews 2005, Issue 1.
16. Hyman S, Diet and Behavior in Young Children with Autism, 2004. http://www.clinicaltrials. gov/ct/show/NCT00090428?order=9.
2. Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with autism. J Child Psychol Psychiatry 2004;45(2):212-29.
3. Lomascolo T, Vaccaio A, Villa S. Autismo: modelli operativi nei servizi. Vannini editrice, 2003.
4. AA.VV. (modificato da Giovanardi, et al. 2001) Allegato VI. Protocollo di valutazione di eventuali patologie associate e di ricerca eziologica nella diagnosi di autismo/DPS. Assistenza alle persone affette da disturbi dello spettro autistico. Dossier 103-2004, Regione Emilia-Romagna, Agenzia Sanitaria Regionale, Bologna, 2005,77-8.
5. Buitelaar JK. Why have drug treatments been so disappointing? Novartis-Found-Symp 2003;251:235-44; discussion 245-9, 281-97.
6. Volkmar FR, Pauls D. Autism, Lancet 2003; 362:1133-41.
7. Montinari M. Autismo: nuove terapie per migliorare e guarire. Macroedizioni, 2002.
8. Shaw W. Biological Treatments for Autism and PPD, revised 2002 edition, con il contributo di Rimland B, et al., edito a cura dell’Autore, Lenexa, USA, 2002.
9. Verzella F, DAN! Italy 2005 (dal sito www.iodellasalute. it), febbraio 2005.
10. Wakefield AJ, Anthony A, Murch SH, Linnell J, Casson DM, Malik M, et al. Ileallymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-41.
11. Hyman S, Levy S. Autistic spectrum disorders: when traditional medicine is not enough. Contemporary Pediatrics 2000;10: 101-12.
12. http://www.autismwebsite.com/ari/dan /pangborn.htm
13. Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Vaisanen ML, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000;15:429-35.
14. Reichelt KL, Knivsberg AM, Hoeien T, Noedland M. A randomised controlled study of dietary intervention in autistic syndromes. Nutritional Neuroscience 2002; 5(4):251-61.
15. Millward C, Ferriter M, Calver S, Connell- Jones G, Gluten- and casein-free diets for autistic spectrum disorder. The Cochrane Database of Systematic Reviews 2005, Issue 1.
16. Hyman S, Diet and Behavior in Young Children with Autism, 2004. http://www.clinicaltrials. gov/ct/show/NCT00090428?order=9.
Corrispondenza: hanau@stat.unibo.it